BioLine Rx Stock (NASDAQ:BLRX), Trade Ideas

BioLine Rx

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Biotech

News

Penny Stocks

Health Care

Movers

General

BLRX

BioLineRx Ltd (NASDAQ: BLRX) announced data from the single-arm pilot phase of the investigator-initiated CheMo4METPANC Phase 2 combination trial of motixafortide and gemcitabine and nab-paclitaxel versus gemcitabine and nab-paclitaxel alone, in first-line 

BioLineRx Touts Encouraging Data From Therapy Trial For First Line Pancreatic Cancer

Price Target

Small Cap

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

ADBE

APLS

Morgan Stanley Capital Protected Notes for S&P 500 Index

NEWR

STAA


	B of A Securities raised the price target for  Unity Software Inc. (NYSE: U) from $46 to $56. B of A Securities analyst Ryan Gee upgraded the stock from Neutral to Buy. Unity Software shares fell 3% to close at $35.71 on Thursday.


Unity Software To Rally Around 60%? Here Are 10 Other Analyst Forecasts For Friday

BioLineRx Highlights Early-Stage Trial Data From Cancer Vaccine Candidate

BioLineRx Ltd. - American Depositary Shares

BioLine Rx Ltd

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) with a Buy and maintains $21 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $21 Price Target

BioLineRx Announces Poster Presentation On Apheresis Center Efficiency And CXCR4 Antagonists Including APHEXDA At ASFA 2024 Annual Meeting Apr. 17-19

Financing

BioLineRx Has Drawn-down The Second Tranche Of $20M Under Its Previously Announced $40M Non-Dilutive Debt Financing Agreement With Funds And Accounts Managed By Blackrock

WIIM

BioLineRx shares are trading lower after the company announced a $6 million registered direct offering.

BioLineRx Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases,&nbsp;today announced that it has entered into definitive agreements with several institutional investors for the issuance and sale in a registered direct offering of 7,500,000 of the Company's American Depositary Shares (ADSs) and warrants to purchase up to an aggregate of 7,500,000 ADSs, at a combined purchase price of $0.80 per ADS and accompanying warrant. Each ADS represents fifteen (15) ordinary shares, par value NIS 0.10 per share, of BioLineRx. The warrants will have an exercise price of $0.80 per ADS, will be exercisable at any time upon issuance and will expire five years from the date of issuance. The offering is expected to close on or about April 1, 2024, subject to the satisfaction of customary closing conditions.
The gross proceeds from the offering (without taking into account any proceeds from any future exercises of warrants), before deducting the placement agent's fees and other offering expenses payable by the Company, are expected to be $6.0 million. BioLineRx intends to use the net proceeds from the offering to support the commercialization of APHEXDA&#xAE; (motixafortide) with an indication in the U.S. for stem cell mobilization for autologous transplantation in patients with multiple myeloma, advance its pancreatic cancer clinical development program and other pipeline programs, and for general corporate purposes.
"We believe that today's equity transaction, when combined with the potential drawdown of an additional $20 million tranche from our existing debt facility at favorable interest rates, together with our existing cash, provides the Company with the financial resources to continue building our momentum with the APHEXDA launch and advancing key life cycle programs for long-term growth opportunities", said Philip Serlin, Chief Executive Officer of BioLineRx.
JonesTrading Institutional Services LLC is acting as the exclusive placement agent for the offering.

Offerings

BioLineRx Announces $6M Registered Direct Offering Of 7.5M ADS And Warrants To Purchase Up To An Aggregate Of 7.5M ADSs, At A Combined Purchase Price Of $0.80 Per ADS And Accompanying Warrant

BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.22) by 31.82 percent. This is a 87.5 percent decrease over losses of $(0.08) per share from the same period last year. The company reported $4.80 million in sales this quarter.

Earnings

BioLine Rx Q4 EPS $(0.15) Beats $(0.22) Estimate, Sales $4.80M

BioLineRx shares are trading lower after the company reported FY23 financial results.

<h3>Gainers</h3>
<ul>
<li>Stoke Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STOK#NASDAQ">STOK</a>) stock increased by 80.2% to $11.71 during Tuesday's pre-market session. The market value of their outstanding shares is at $522.8 million. As per the press release, Q4 earnings came out yesterday. </li>
<li>OpGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPGN#NASDAQ">OPGN</a>) shares moved upwards by 77.6% to $0.84. The market value of their outstanding shares is at $8.4 million. </li>
<li>ABVC BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABVC#NASDAQ">ABVC</a>) stock increased by 45.71% to $1.53. The market value of their outstanding shares is at $16.1 million. </li>
<li>Mesoblast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) shares moved upwards by 32.27% to $2.91. The market value of their outstanding shares is at $295.3 million. </li>
<li>Praxis Precision Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRAX#NASDAQ">PRAX</a>) shares increased by 21.38% to $61.3. The market value of their outstanding shares is at $811.5 million. </li>
<li>Sutro Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRO#NASDAQ">STRO</a>) stock moved upwards by 18.96% to $3.89. The company's market cap stands at $237.1 million. The company's, Q4 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NeuBase Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBSE#NASDAQ">NBSE</a>) stock decreased by 55.0% to $0.45 during Tuesday's pre-market session. The company's market cap stands at $1.6 million. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares fell 14.49% to $1.24. The company's market cap stands at $1.8 million. The company's, Q4 earnings came out yesterday. </li>
<li>bluebird bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) shares fell 12.51% to $1.19. The company's market cap stands at $229.3 million. As per the press release, Q4 earnings came out today. </li>
<li>BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) stock declined by 11.54% to $1.15. The market value of their outstanding shares is at $83.3 million. The company's, Q4 earnings came out today. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) stock fell 8.48% to $0.23. The market value of their outstanding shares is at $2.0 million. </li>
<li>IMAC Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BACK#NASDAQ">BACK</a>) stock decreased by 8.27% to $2.22. The company's market cap stands at $2.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABVC

BACK

BLUE

ISPC

MESO

NBSE

OPGN

PRAX

STOK

STRO

TIVC

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

BioLineRx FY23 Total Revenues $4.8M, EPS $(0.06)

<h3>Companies Reporting Before The Bell</h3>
&bull; bluebird bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million.
&bull; AIM ImmunoTech (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIM#AMEX">AIM</a>) is estimated to report earnings for its fourth quarter.
&bull; Elbit Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLT#NASDAQ">ESLT</a>) is projected to report quarterly earnings at $1.38 per share on revenue of $1.52 billion.
&bull; GDS Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>) is likely to report quarterly loss at $0.33 per share on revenue of $357.63 million.
&bull; Bragg Gaming Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRAG#NASDAQ">BRAG</a>) is estimated to report quarterly loss at $0.01 per share on revenue of $37.82 million.
&bull; BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) is expected to report earnings for its fourth quarter.
&bull; Zhihu (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZH#NYSE">ZH</a>) is likely to report quarterly loss at $0.04 per share on revenue of $148.11 million.
&bull; DouYu Intl Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOYU#NASDAQ">DOYU</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $170.91 million.
&bull; Waterdrop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WDH#NYSE">WDH</a>) is estimated to report quarterly earnings at $0.01 per share on revenue of $94.55 million.
&bull; Forza X1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRZA#NASDAQ">FRZA</a>) is likely to report earnings for its fourth quarter.
&bull; Acumen Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABOS#NASDAQ">ABOS</a>) is likely to report earnings for its fourth quarter.
&bull; Twin Vee PowerCats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEEE#NASDAQ">VEEE</a>) is likely to report earnings for its fourth quarter.
&bull; Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) is expected to report quarterly loss at $0.51 per share on revenue of $540 thousand.
&bull; Volato Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SOAR#AMEX">SOAR</a>) is estimated to report earnings for its fourth quarter.
&bull; Movado Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOV#NYSE">MOV</a>) is likely to report quarterly earnings at $0.39 per share on revenue of $174.80 million.
&bull; Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) is estimated to report earnings for its fourth quarter.
&bull; McCormick &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MKC#NYSE">MKC</a>) is expected to report quarterly earnings at $0.58 per share on revenue of $1.56 billion.
&bull; Kaspi.kz (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSPI#NASDAQ">KSPI</a>) is estimated to report earnings for its first quarter.
&bull; TD Synnex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) is likely to report quarterly earnings at $2.84 per share on revenue of $14.36 billion.
<h3>Companies Reporting After The Bell</h3>
&bull; Sidus Space (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIDU#NASDAQ">SIDU</a>) is estimated to report earnings for its fourth quarter.
&bull; Marpai (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRAI#NASDAQ">MRAI</a>) is estimated to report earnings for its fourth quarter.
&bull; NovaBay Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NBY#AMEX">NBY</a>) is likely to report quarterly loss at $0.30 per share on revenue of $3.40 million.
&bull; Aptose Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) is projected to report earnings for its fourth quarter.
&bull; Direct Digital Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRCT#NASDAQ">DRCT</a>) is likely to report quarterly earnings at $0.26 per share on revenue of $65.95 million.
&bull; US Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USEG#NASDAQ">USEG</a>) is expected to report quarterly loss at $0.03 per share on revenue of $8.87 million.
&bull; X Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYF#NYSE">XYF</a>) is likely to report earnings for its fourth quarter.
&bull; Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) is likely to report quarterly loss at $0.05 per share on revenue of $14.90 million.
&bull; iPath Series B Carbon Exchange-Traded Notes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRN#NYSE">GRN</a>) is projected to report quarterly loss at $0.01 per share on revenue of $13.40 million.
&bull; Intrusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTZ#NASDAQ">INTZ</a>) is likely to report quarterly loss at $0.11 per share on revenue of $1.64 million.
&bull; BioAtla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) is expected to report earnings for its fourth quarter.
&bull; GameStop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) is likely to report quarterly earnings at $0.29 per share on revenue of $2.05 billion.
&bull; Forge Global Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRGE#NYSE">FRGE</a>) is likely to report quarterly loss at $0.10 per share on revenue of $19.57 million.
&bull; Biora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOR#NASDAQ">BIOR</a>) is expected to report earnings for its fourth quarter.
&bull; ProSomnus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSA#NASDAQ">OSA</a>) is expected to report quarterly loss at $0.31 per share on revenue of $7.37 million.
&bull; ATA Creativity Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AACG#NASDAQ">AACG</a>) is likely to report earnings for its fourth quarter.
&bull; Noah Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOAH#NYSE">NOAH</a>) is estimated to report earnings for its fourth quarter.
&bull; PAVmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAVM#NASDAQ">PAVM</a>) is projected to report quarterly loss at $1.89 per share on revenue of $1.05 million.
&bull; AEye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIDR#NASDAQ">LIDR</a>) is likely to report quarterly loss at $1.20 per share on revenue of $100 thousand.
&bull; Velo3D (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLD#NYSE">VLD</a>) is likely to report quarterly loss at $0.08 per share on revenue of $19.50 million.
&bull; Progress Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRGS#NASDAQ">PRGS</a>) is expected to report quarterly earnings at $1.14 per share on revenue of $181.91 million.
&bull; WidePoint (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/WYY#AMEX">WYY</a>) is estimated to report earnings for its fourth quarter.
&bull; LuxUrban Hotels (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUXH#NASDAQ">LUXH</a>) is expected to report quarterly earnings at $0.09 per share on revenue of $34.20 million.
&bull; Oxbridge Re Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OXBR#NASDAQ">OXBR</a>) is expected to report earnings for its fourth quarter.
&bull; Concentrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) is estimated to report quarterly earnings at $2.58 per share on revenue of $2.38 billion.
&bull; Ouster (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NYSE">OUST</a>) is likely to report quarterly loss at $0.83 per share on revenue of $24.06 million.
&bull; Ncino (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNO#NASDAQ">NCNO</a>) is expected to report quarterly earnings at $0.12 per share on revenue of $124.62 million.
&bull; PaySign (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYS#NASDAQ">PAYS</a>) is projected to report quarterly earnings at $0.02 per share on revenue of $12.62 million.
&bull; Ryvyl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVYL#NASDAQ">RVYL</a>) is estimated to report quarterly loss at $0.40 per share on revenue of $18.00 million.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

AACG

ABOS

APTO

BCAB

BIOR

BRAG

CGTX

CNXC

DCTH

DOYU

DRCT

ESLT

FRGE

FRZA

INTZ

IRIX

KSPI

LIDR

LUXH

MRAI

NCNO

NOAH

OUST

OXBR

PAVM

PAYS

PRGS

RVYL

SIDU

SOAR

USEG

VEEE

Earnings Scheduled For March 26, 2024

BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) is set to give its latest quarterly earnings report on Tuesday, 2024-03-26. Here's what investors need to know before the announcement.
Analysts estimate that BioLine Rx will report an earnings per share (EPS) of $-0.26. 
BioLine Rx bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company missed EPS by $0.05, which was followed by a 10.59% drop in the share price the next day.
Here's a look at BioLine Rx's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.21</td>
<td></td>
<td></td>
<td>-0.14</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.26</td>
<td>-0.3</td>
<td>-0.1</td>
<td>-0.08</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-11.0%</td>
<td>26.0%</td>
<td>-1.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<h3>Stock Performance</h3>
Shares of BioLine Rx were trading at $1.38 as of March 22. Over the last 52-week period, shares are up 55.74%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/BLRX/earnings">To track all earnings releases for BioLine Rx visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview For BioLine Rx

BioLineRx Announces Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production, New Patent, When Issued, Will Be Valid Until December 2041

Biolinerx Announced First Patient Dosed In Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide In First-line Pancreatic Cancer

BioLineRx Discloses Acceptance Of Two Poster Presentations On APHEXDA (motixafortide) For CD34+ Hematopoietic Stem Cell (HSC) Mobilization In Patients With Multiple Myeloma At 2024 Tandem Meetings Of ASTCT And CIBMTR

BioLineRx Says First Patient Has Been Dosed In Phase 1 Trial Of Motixafortide As Monotherapy And In Combination With Natalizumab For CD34+ Hematopoietic Stem Cell Mobilization For Gene Therapies In Sickle Cell Disease

<h3>Companies Reporting Before The Bell</h3>
&bull; Greenland Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTEC#NASDAQ">GTEC</a>) is projected to report quarterly earnings at $0.05 per share on revenue of $24.26 million.
&bull; Pyxis Tankers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXS#NASDAQ">PXS</a>) is estimated to report quarterly earnings at $0.19 per share on revenue of $8.25 million.
&bull; BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) is estimated to report earnings for its third quarter.
&bull; ReNew Energy Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNW#NASDAQ">RNW</a>) is likely to report quarterly earnings at $0.10 per share on revenue of $109.71 million.
&bull; So-Young Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SY#NASDAQ">SY</a>) is projected to report quarterly earnings at $0.02 per share on revenue of $55.38 million.
&bull; Enlight Renewable Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENLT#NASDAQ">ENLT</a>) is estimated to report quarterly earnings at $0.10 per share on revenue of $65.70 million.
&bull; Legend Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NASDAQ">LEGN</a>) is projected to report earnings for its third quarter.
&bull; Zepp Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZEPP#NYSE">ZEPP</a>) is projected to report quarterly earnings at $0.03 per share on revenue of $179.52 million.
&bull; Full Truck Alliance Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YMM#NYSE">YMM</a>) is projected to report earnings for its third quarter.
&bull; VEON (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEON#NASDAQ">VEON</a>) is expected to report earnings for its third quarter.
&bull; Fanhua (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANH#NASDAQ">FANH</a>) is expected to report earnings for its third quarter.
&bull; Niu Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIU#NASDAQ">NIU</a>) is expected to report earnings for its third quarter.
<h3>Companies Reporting After The Bell</h3>
&bull; Techprecision (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPCS#NASDAQ">TPCS</a>) is expected to report earnings for its second quarter.
&bull; Xcel Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XELB#NASDAQ">XELB</a>) is likely to report quarterly loss at $0.16 per share on revenue of $3.40 million.
&bull; Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) is expected to report quarterly earnings at $0.07 per share on revenue of $735.32 million.
&bull; Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENT#NASDAQ">CENT</a>) is projected to report quarterly earnings at $0.07 per share on revenue of $735.32 million.
&bull; Remark Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARK#NASDAQ">MARK</a>) is estimated to report earnings for its third quarter.
&bull; Presto Automation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRST#NASDAQ">PRST</a>) is projected to report earnings for its third quarter.
&bull; Polished.com (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/POL#AMEX">POL</a>) is likely to report earnings for its third quarter.
&bull; Upexi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPXI#NASDAQ">UPXI</a>) is expected to report quarterly loss at $0.04 per share on revenue of $26.52 million.
&bull; Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) is expected to report quarterly loss at $2.00 per share on revenue of $20.60 million.
&bull; Yalla Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YALA#NYSE">YALA</a>) is estimated to report earnings for its third quarter.
&bull; Symbotic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) is estimated to report quarterly loss at $0.12 per share on revenue of $305.16 million.
&bull; FinVolution Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FINV#NYSE">FINV</a>) is likely to report earnings for its third quarter.
&bull; Trip.com Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>) is estimated to report earnings for its third quarter.
&bull; Keysight Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEYS#NYSE">KEYS</a>) is estimated to report quarterly earnings at $1.87 per share on revenue of $1.30 billion.
&bull; Fidelis Insurance Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIHL#NYSE">FIHL</a>) is projected to report earnings for its third quarter.
&bull; Zoom Video Comms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) is projected to report quarterly earnings at $1.08 per share on revenue of $1.12 billion.
&bull; BellRing Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRBR#NYSE">BRBR</a>) is likely to report quarterly earnings at $0.39 per share on revenue of $460.52 million.
&bull; FS Credit Opp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSCO#NYSE">FSCO</a>) is expected to report earnings for its third quarter.
&bull; Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) is projected to report quarterly earnings at $1.35 per share on revenue of $1.68 billion.
&bull; Golub Capital BDC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GBDC#NASDAQ">GBDC</a>) is estimated to report quarterly earnings at $0.47 per share on revenue of $157.82 million.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

BRBR

CENT

CENTA

ENLT

ENTA

FANH

FIHL

FINV

FSCO

GBDC

GTEC

KEYS

LEGN

MARK

PRST

TCOM

TPCS

UPXI

VEON

XELB

YALA

ZEPP

Earnings Scheduled For November 20, 2023

Guidance

BioLine Rx Says Cash, Cash Equivalents And Short-Term Bank Deposits Of $26M And Consideration From Exclusive License Agreement And Securities Purchase Agreement Of $29.6M Can Provide Cash Runway Into 2025

BioLine RX Ltd - ADR (BLRX) surpassed earnings projections on 3/26/2024 for Q4 2023.The consensus among analysts for Biolinerx Ltd ADR was for an earnings per share (EPS) loss of $0.22 per share. The firm was able to surpass those projections, reporting an EPS loss of $0.15 per share, a positive surprise of $0 (32%). Profi

Biolinerx Ltd ADR Down 11.54% To $1.15 After Earnings

BioLineRx Ltd. (BLRX) Q4 2023 Earnings Call Transcript

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Bioline RX Ltd Sponsored ADR (BLRX – Research Report),...

Buy Rating Affirmed for BioLineRx: Strong Financials and Expanding Market Presence Fuel Analyst Optimism

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
BioLine Rx (NASDAQ:<a href="https://investorplace.com/stock-quotes/blrx-stock-quote/">BLRX</a>) just reported results for the fourth quarter of 2023.<ul><li>BioLine Rx reported earnings per share of -15 cents. This was above the analyst estimate for EPS of -22 cents.</li><li>The company reported revenue of $4.80 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT793992">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/02/wall-street-legend-issues-urgent-ai-code-red/?cid=MKT781156&amp;eid=MKT793990">&ldquo;America&rsquo;s Top Trader&rdquo; Issues A.I. Code Red: Act Now or Miss Out</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793999">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/03/blrx-stock-earnings-bioline-rx-for-q4-of-2023/">BLRX Stock Earnings: BioLine Rx Beats EPS for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

BLRX Stock Earnings: BioLine Rx Beats EPS for Q4 2023

These Healthcare stocks are trading higher:-Stoke Therapeutics Inc (STOK) stock is trading at $10.98, an increase of $4.48, or 70%, on high volume.  Stoke Therapeutics Inc gets a Sentiment Score of Bullish from InvestorsObserver and receives an average analyst recommendation of Strong Buy with a price target of $19.86.  -N

Healthcare Stocks Moving Up and Down Tuesday: STOK, NUVB, RVPH, CRDL, EQ, PRE, BLRX, GLUE

Overall market sentiment has been down on BioLine RX Ltd - ADR (BLRX)  stock lately. BLRX receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator. BioLine RX Ltd - ADR has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on BLRX!See Full BLRX ReportWhat is St

Should You Buy BioLine RX Ltd - ADR (BLRX) Stock After it Is Down 8.40% in a Week?

BioLineRx to raise $6M through a direct offering

Bioline RX Ltd Sponsored ADR (BLRX) has released an update. BiolineRx Ltd., an Israeli company, has successfully completed a registered direct offe...

BiolineRx Ltd. Completes Significant Securities Offering

Bioline RX Ltd Sponsored ADR (BLRX) has released an update. BioLineRx Ltd. has announced a poster presentation on their product, APHEXDA (motixafor...

BioLineRx Enhances Multiple Myeloma Treatment

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Bioline RX Ltd Sponsored ADR (BLRX – Research Report), retaining the price t...

Buy Rating on Bioline RX Ltd for Breakthrough Stem Cell Mobilization and Enhanced Apheresis Efficiency

CRDL

GLUE

NUVB

RVPH

Press Releases

BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates

BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease

BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)

BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production

BioLineRx to Report 2023 Annual Financial Results on March 26, 2024

BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates

BioLineRx Announces $6 Million Registered Direct Offering

BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement

BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting